PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Prospective assessment of oral mucositis and its impact on quality of life and patient-reported outcomes during radiotherapy for head and neck cancer.

Abstract Oral mucositis (OM) is a common acute side effect during radiotherapy treatments for head and neck cancer (HNC), with a potential impact on patient's compliance to therapy, quality of life (QoL) and clinical outcomes. Its timely and appropriate management is of paramount importance. Several quantitative scoring scales are available to properly assess OM and its influence on patient-reported outcomes (PROs) and QoL. We prospectively assessed OM in a cohort of HNC patients submitted to radiation using the Oral Mucositis Assessment Scale (OMAS), while its impact on PROs and QoL was evaluated employing the Oral Mucositis Weekly Questionnaire-Head and Neck Cancer (OMWQ-HN) and the Functional Assessment of Cancer Therapy-Head and Neck Cancer (FACT-HN). Evaluation of OMAS scores highlighted a progressive increase in OM during treatment and a partial recovery after the end of radiation. These trends were correlated to PROs and QoL as evaluated with OMWQ-HN and FACT-HN questionnaires. In the present study, we provided a quantitative assessment of OM, PROs and QoL in HNC patient undergoing radiotherapy, potentially useful for future comparison.
PMID
Related Publications

The M. D. Anderson symptom inventory-head and neck module, a patient-reported outcome instrument, accurately predicts the severity of radiation-induced mucositis.

Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life.

Phenylbutyrate mouthwash mitigates oral mucositis during radiotherapy or chemoradiotherapy in patients with head-and-neck cancer.

Effect of low-level laser therapy on patient reported measures of oral mucositis and quality of life in head and neck cancer patients receiving chemoradiotherapy--a randomized controlled trial.

Longitudinal evaluation of the oral mucositis weekly questionnaire-head and neck cancer, a patient-reported outcomes questionnaire.

Authors

Mayor MeshTerms
Keywords

Concomitant chemo-radiotherapy

Head and neck cancer

Oral mucositis

Patient-reported outcomes

Quality of life

Journal Title medical oncology (northwood, london, england)
Publication Year Start




PMID- 28386836
OWN - NLM
STAT- MEDLINE
DA  - 20170407
DCOM- 20170419
LR  - 20170419
IS  - 1559-131X (Electronic)
IS  - 1357-0560 (Linking)
VI  - 34
IP  - 5
DP  - 2017 May
TI  - Prospective assessment of oral mucositis and its impact on quality of life and
      patient-reported outcomes during radiotherapy for head and neck cancer.
PG  - 81
LID - 10.1007/s12032-017-0950-1 [doi]
AB  - Oral mucositis (OM) is a common acute side effect during radiotherapy treatments 
      for head and neck cancer (HNC), with a potential impact on patient's compliance
      to therapy, quality of life (QoL) and clinical outcomes. Its timely and
      appropriate management is of paramount importance. Several quantitative scoring
      scales are available to properly assess OM and its influence on patient-reported 
      outcomes (PROs) and QoL. We prospectively assessed OM in a cohort of HNC patients
      submitted to radiation using the Oral Mucositis Assessment Scale (OMAS), while
      its impact on PROs and QoL was evaluated employing the Oral Mucositis Weekly
      Questionnaire-Head and Neck Cancer (OMWQ-HN) and the Functional Assessment of
      Cancer Therapy-Head and Neck Cancer (FACT-HN). Evaluation of OMAS scores
      highlighted a progressive increase in OM during treatment and a partial recovery 
      after the end of radiation. These trends were correlated to PROs and QoL as
      evaluated with OMWQ-HN and FACT-HN questionnaires. In the present study, we
      provided a quantitative assessment of OM, PROs and QoL in HNC patient undergoing 
      radiotherapy, potentially useful for future comparison.
FAU - Franco, Pierfrancesco
AU  - Franco P
AUID- ORCID: http://orcid.org/0000-0003-2276-0687
AD  - Department of Oncology, Radiation Oncology, School of Medicine, University of
      Turin, Via Genova 3, 10126, Turin, Italy. [email protected]
FAU - Martini, Stefania
AU  - Martini S
AD  - Department of Oncology, Radiation Oncology, School of Medicine, University of
      Turin, Via Genova 3, 10126, Turin, Italy.
FAU - Di Muzio, Jacopo
AU  - Di Muzio J
AD  - Department of Oncology, Radiation Oncology, School of Medicine, University of
      Turin, Via Genova 3, 10126, Turin, Italy.
FAU - Cavallin, Chiara
AU  - Cavallin C
AD  - Department of Oncology, Radiation Oncology, School of Medicine, University of
      Turin, Via Genova 3, 10126, Turin, Italy.
FAU - Arcadipane, Francesca
AU  - Arcadipane F
AD  - Department of Oncology, Radiation Oncology, AOU Citta' della Salute e della
      Scienza, Turin, Italy.
FAU - Rampino, Monica
AU  - Rampino M
AD  - Department of Oncology, Radiation Oncology, AOU Citta' della Salute e della
      Scienza, Turin, Italy.
FAU - Ostellino, Oliviero
AU  - Ostellino O
AD  - Department of Oncology, 2nd Medical Oncology Division, AOU Citta della Salute e
      della Scienza, Turin, Italy.
FAU - Pecorari, Giancarlo
AU  - Pecorari G
AD  - Department of Surgical Sciences, 1st ENT Division, University of Turin, Turin,
      Italy.
FAU - Garzino Demo, Paolo
AU  - Garzino Demo P
AD  - Department of Surgical Sciences, Maxillofacial Surgery Division, University of
      Turin, Turin, Italy.
FAU - Fasolis, Massimo
AU  - Fasolis M
AD  - Department of Surgical Sciences, Maxillofacial Surgery Division, University of
      Turin, Turin, Italy.
FAU - Airoldi, Mario
AU  - Airoldi M
AD  - Department of Oncology, 2nd Medical Oncology Division, AOU Citta della Salute e
      della Scienza, Turin, Italy.
FAU - Ricardi, Umberto
AU  - Ricardi U
AD  - Department of Oncology, Radiation Oncology, School of Medicine, University of
      Turin, Via Genova 3, 10126, Turin, Italy.
LA  - eng
PT  - Journal Article
DEP - 20170406
PL  - United States
TA  - Med Oncol
JT  - Medical oncology (Northwood, London, England)
JID - 9435512
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Chemoradiotherapy
MH  - Female
MH  - Head and Neck Neoplasms/drug therapy/*radiotherapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Quality of Life
MH  - Radiation Injuries/*diagnosis/etiology/physiopathology
MH  - Stomatitis/*diagnosis/etiology/physiopathology
OTO - NOTNLM
OT  - Concomitant chemo-radiotherapy
OT  - Head and neck cancer
OT  - Oral mucositis
OT  - Patient-reported outcomes
OT  - Quality of life
EDAT- 2017/04/08 06:00
MHDA- 2017/04/20 06:00
CRDT- 2017/04/08 06:00
PHST- 2017/03/14 [received]
PHST- 2017/04/04 [accepted]
AID - 10.1007/s12032-017-0950-1 [doi]
AID - 10.1007/s12032-017-0950-1 [pii]
PST - ppublish
SO  - Med Oncol. 2017 May;34(5):81. doi: 10.1007/s12032-017-0950-1. Epub 2017 Apr 6.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>